Arecor Therapeutics (LON:AREC) Shares Down 3.9% – Should You Sell?

Arecor Therapeutics plc (LON:AREC)’s stock price was down 3.9% during trading on Thursday . The company traded as low as GBX 61 and last traded at GBX 61. Approximately 45,533 shares traded hands during trading, an increase of 122% from the average session volume of 20,513 shares. The stock had previously closed at GBX 63.50.

Arecor Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.52, a current ratio of 4.35 and a quick ratio of 6.24. The stock has a 50 day moving average price of GBX 66.39 and a two-hundred day moving average price of GBX 73.30. The firm has a market capitalization of £23.03 million, a price-to-earnings ratio of 30.50 and a beta of -0.18.

Arecor Therapeutics (LON:AREC) last posted its quarterly earnings data on Monday, April 13th. The company reported GBX 2 earnings per share (EPS) for the quarter. Arecor Therapeutics had a return on equity of 14.26% and a net margin of 38.74%.The firm had revenue of GBX 171 million for the quarter. As a group, analysts expect that Arecor Therapeutics plc will post -0.35 EPS for the current year.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.